# Joe Loy

> Joe Loy is the President and CEO of Zetagen Therapeutics, a Syracuse, New York clinical-stage biopharmaceutical company developing small-molecule therapies to treat metastatic cancer in bone and soft tissue while regenerating healthy bone. A serial entrepreneur with several successful exits, Loy has spent his career building teams around first-to-market medical technologies at companies including US Surgical, Pfizer/Leibinger, NuVasive, and Stryker. Since taking the helm in January 2019, he has guided Zetagen through two FDA Breakthrough Device Designations, multiple financing rounds, and the launch of Phase 2a clinical trials for its lead candidate ZetaMet.

- **Role:** President & CEO at Zetagen Therapeutics
- **Organizations:** Zetagen Therapeutics, US Surgical, Pfizer/Leibinger, NuVasive, Stryker
- **Nationality:** American
- **Education:** B.S. in Business Administration and Management, Oklahoma State University
- **Known for:** Led Zetagen Therapeutics to two FDA Breakthrough Device Designations (ZetaMet and ZetaFuse), Advanced ZetaMet into Phase 2a clinical trials for metastatic breast cancer bone lesions, Closed multiple financing rounds, including an oversubscribed Series B1 (~$12.9M)

## Career timeline

- **earlier career** — Held executive positions of increasing responsibility at US Surgical, Pfizer/Leibinger, NuVasive, and Stryker
- **2019** — Joined Zetagen Therapeutics as Chief Executive Officer in January
- **2021** — Zetagen secured FDA Breakthrough Device Designations for its lead technologies
- **2023** — Closed $9.79M Series B funding round for ZetaMet and ZetaMAST
- **2024** — Announced first patients enrolled in Phase 2a clinical study of ZetaMet for metastatic breast cancer
- **2025** — Closed oversubscribed Series B1 round (~$12.9M) on strength of Phase 2a data

## Achievements

- Led Zetagen Therapeutics to two FDA Breakthrough Device Designations (ZetaMet and ZetaFuse)
- Advanced ZetaMet into Phase 2a clinical trials for metastatic breast cancer bone lesions
- Closed multiple financing rounds, including an oversubscribed Series B1 (~$12.9M)
- Expanded clinical trial approvals internationally, including Health Canada and Australia
- Serial entrepreneur with several successful business exits across medical technology

## Latest updates

- **2024-11** — Zetagen announced the first patients enrolled in its Phase 2a clinical study of ZetaMet for metastatic breast cancer bone lesions.
- **2025-11** — Zetagen closed an oversubscribed Series B1 financing round of roughly $12.9M on the strength of promising Phase 2a data and its pipeline.

## Links

- Website: https://zetagen.com
- LinkedIn: https://www.linkedin.com/in/joe-c-loy-09160333
- Twitter/X: https://twitter.com/ZetaGenTx
- Facebook: https://facebook.com/pages/category/Medical---Health/ZetaGen-Therapeutics-2102529683321846/

---

Profile page: https://yespress.io/joe-loy
Published by YesPress — https://yespress.io
Last updated: 2026-07-16